- Home
- HPK vs IMNM Comparison
HPK vs IMNM Comparison
Compare HPK & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPK
- IMNM
- Stock Information
- Founded
- HPK 2019
- IMNM 2006
- Country
- HPK United States
- IMNM United States
- Employees
- HPK N/A
- IMNM N/A
- Industry
- HPK Oil & Gas Production
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- HPK Energy
- IMNM Health Care
- Exchange
- HPK Nasdaq
- IMNM Nasdaq
- Market Cap
- HPK 1.1B
- IMNM 945.8M
- IPO Year
- HPK N/A
- IMNM 2020
- Fundamental
- Price
- HPK $7.69
- IMNM $10.30
- Analyst Decision
- HPK Sell
- IMNM Strong Buy
- Analyst Count
- HPK 2
- IMNM 7
- Target Price
- HPK $11.50
- IMNM $24.57
- AVG Volume (30 Days)
- HPK 637.4K
- IMNM 629.1K
- Earning Date
- HPK 08-11-2025
- IMNM 08-06-2025
- Dividend Yield
- HPK 2.07%
- IMNM N/A
- EPS Growth
- HPK N/A
- IMNM N/A
- EPS
- HPK 0.86
- IMNM N/A
- Revenue
- HPK $964,232,000.00
- IMNM $12,589,000.00
- Revenue This Year
- HPK N/A
- IMNM N/A
- Revenue Next Year
- HPK N/A
- IMNM $154.73
- P/E Ratio
- HPK $8.99
- IMNM N/A
- Revenue Growth
- HPK N/A
- IMNM 16.74
- 52 Week Low
- HPK $7.00
- IMNM $5.15
- 52 Week High
- HPK $16.56
- IMNM $16.73
- Technical
- Relative Strength Index (RSI)
- HPK 40.65
- IMNM 53.80
- Support Level
- HPK $7.08
- IMNM $9.37
- Resistance Level
- HPK $7.79
- IMNM $10.39
- Average True Range (ATR)
- HPK 0.54
- IMNM 0.49
- MACD
- HPK -0.03
- IMNM -0.06
- Stochastic Oscillator
- HPK 32.39
- IMNM 52.81
About HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.